MedTrace Logo

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

NCT03125577 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-08

No results posted yet for this study

Summary

The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Conditions

Interventions

BIOLOGICAL

4SCAR19 and 4SCAR22

4SCAR19 and 4SCAR22

BIOLOGICAL

4SCAR19 and 4SCAR38

4SCAR19 and 4SCAR38

BIOLOGICAL

4SCAR19 and 4SCAR20

4SCAR19 and 4SCAR20

BIOLOGICAL

4SCAR19 and 4SCAR123

4SCAR19 and 4SCAR123

BIOLOGICAL

4SCAR19 and 4SCAR70

4SCAR19 and 4SCAR70

BIOLOGICAL

4SCAR19 and 4SCAR30

4SCAR19 and 4SCAR30

Sponsors & Collaborators

  • Shenzhen Geno-Immune Medical Institute

    lead OTHER

Principal Investigators

  • Lung-Ji Chang, PhD · Shenzhen Geno-Immune Medical Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03125577 on ClinicalTrials.gov